Enliven Therapeutics, Inc. (ELVN)

NASDAQ: ELVN · Real-Time Price · USD

21.81

+0.41 (1.92%)

At close: Dec 5, 2025, 4:00 PM EST

22.24

+0.43 (1.97%)

After-hours: Dec 5, 2025, 6:16 PM EST

Enliven Therapeutics Employees

Enliven Therapeutics had 62 employees as of December 31, 2024. The number of employees increased by 16 or 34.78% compared to the previous year.

Employees

62

Change (1Y)

16

Growth (1Y)

34.78%

Revenue / Employee

n/a

Profits / Employee

-$1,567,855

Market Cap

1.29B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	62	16	34.78%
Dec 31, 2023	46	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

ELVN News

17 days ago - Enliven Therapeutics: Notable Early Signals, But Too Many Assumptions To Justify A Buy - Seeking Alpha
23 days ago - Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update - PRNewsWire
3 months ago - Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting - PRNewsWire
4 months ago - Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update - PRNewsWire
6 months ago - Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - PRNewsWire
6 months ago - Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - PRNewsWire
6 months ago - Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - PRNewsWire
6 months ago - Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress - PRNewsWire